T1	Participants 70 84	uveal melanoma
T2	Participants 127 141	Uveal melanoma
T3	Participants 389 403	uveal melanoma
T4	Participants 439 485	Randomized, open-label, phase 2 clinical trial
T5	Participants 524 686	conducted from August 2010 through December 2013 among 120 patients with metastatic uveal melanoma at 15 academic oncology centers in the United States and Canada
T6	Participants 702 757	One hundred one patients were randomized in a 1:1 ratio
T7	Participants 1123 1251	19 patients were registered and 18 treated with selumetinib without randomization to complete the planned 120-patient enrollment
